1471-2164-14-265 1471-2164 Methodology article <p>Simultaneous miRNA and mRNA transcriptome profiling of human myoblasts reveals a novel set of myogenic differentiation-associated miRNAs and their target genes</p> DmitrievPetrpetr.dmitirev@gmail.com BaratAnaana.barat.leonidovna@gmail.com PolesskayaAnnaanna.polesskaya@cea.fr O’ConnellJMaryoconnell@dcu.edu.ie RobertThomasthomas.robert@igr.fr DessenPhilippedessen@igr.fr WalshAThomaswalsh@dcu.edu.ie LazarVladimirlazar@igr.fr TurkiAhmedahmed.turki@inderm.fr CarnacGillesgilles.carnac@inserm.fr Laoudj-ChenivesseDalilaDalila.Laoudj-Chenivesse@inserm.fr LipinskiMarclipinski@igr.fr VassetzkySYegorvassetzky@igr.fr

UMR 8126, Univ. Paris-Sud 11, CNRS, Institut de Cancérologie Gustave-Roussy, 39, rue Camille-Desmoulins, Villejuif 94805, France

INSERM U-1046, 371 Avenue du Doyen Gaston Giraud, Montpellier, F-34295, France

Institut de Cancérologie Gustave-Roussy, Villejuif, F-94805, France

Bioinformatics and Molecular Evolution Group, School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland

CNRS FRE 3377, CEA Saclay, Gif-sur-Yvette, F-91191, France

BMC Genomics
<p>Human and rodent genomics</p>
1471-2164 2013 14 1 265 http://www.biomedcentral.com/1471-2164/14/265 10.1186/1471-2164-14-26523597168
1911201226320131842013 2013Dmitriev et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. microRNA Skeletal muscle Myogenesis Myoblast

Abstract

Background

miRNA profiling performed in myogenic cells and biopsies from skeletal muscles has previously identified miRNAs involved in myogenesis.

Results

Here, we have performed miRNA transcriptome profiling in human affinity-purified CD56+ myoblasts induced to differentiate in vitro. In total, we have identified 60 miRNAs differentially expressed during myogenic differentiation. Many were not known for being differentially expressed during myogenic differentiation. Of these, 14 (miR-23b, miR-28, miR-98, miR-103, miR-107, miR-193a, miR-210, miR-324-5p, miR-324-3p, miR-331, miR-374, miR-432, miR-502, and miR-660) were upregulated and 6 (miR-31, miR-451, miR-452, miR-565, miR-594 and miR-659) were downregulated. mRNA transcriptome profiling performed in parallel resulted in identification of 6,616 genes differentially expressed during myogenic differentiation.

Conclusions

This simultaneous miRNA/mRNA transcriptome profiling allowed us to predict with high accuracy target genes of myogenesis-related microRNAs and to deduce their functions.

Background

MicroRNAs (miRNAs) are 20–25 nt-long non-coding RNAs transcribed predominantly by the RNA polymerase II 1 2 . miRNAs play an important role in regulating gene expression at the protein and mRNA levels. They have been previously shown to inhibit translation initiation and elongation and induce deadenylation and degradation of mRNA (for review see 3 ). In addition, there are indications that miRNAs may also activate translation 4 .

Along with transcription factors, miRNAs contribute to skeletal myogenesis (for review see 5 ). Myogenic microRNAs miR-1, miR-133a/b and miR-206 (also called MyomiRs, as suggested by 6 ) regulate myogenic differentiation and proliferation of myogenic cells by targeting important regulators of myogenesis 7 8 (for review see 6 9 ). MiR-1 and miR-133a are expressed in both skeletal and cardiac muscles 7 10 , while miR-133b and miR-206 are expressed solely in skeletal muscles 10 .

Most miRNAs expressed in skeletal muscles are found to be upregulated during myogenesis. These include miR-24 11 , miR-26a 12 , miR-27b 13 , miR-29b/c 14 , miR-143 15 , miR-181 16 , miR-208b/499 17 , miR-214 18 , miR-322/424 and miR-503 19 , miR-486 20 , miR-682 21 . Only few known miRNAs are involved in the regulation of myogenic differentiation are downregulated during myogenesis. These include miR-125b 22 and miR-221/222 23 (for review see 5 24 25 ).

Altogether, myogenesis-related miRNAs have been studied during myogenic differentiation of human primary myoblasts 14 15 26 27 and in various model systems, e.g. the immortalized murine cell line C2C12 12 16 20 28 , murine primary satellite cells and myogenic progenitor cells 21 as well as quail myoblasts 29 . Several myogenesis-related miRNAs have been discovered or confirmed by expression profiling of developing muscular tissues in humans 30 , pigs 31 and in the common carp 32 (Table 1).

<p>Table 1</p>

microRNA

This study

Human (homo sapiens)

Mouse (Mus musculus)

Pig

Common carp

In bold are human-specific MR-miRs (hMR-miRs, 16 in total); Italicized are microRNAs shown to be differentially expressed during myogenesis in non- human cells; microRNAs with a known function in myogenesis are

    underscored
. (n): microRNAs that we have shown to be differentially expressed during myogenesis for the first time in our study. The number of arrows corresponds to the level of up- or downregulation of microRNAs. One arrow: fold change 1 to 3 fold, two arrows: fold change 3 to 7 times, three arrows: fold change 7 to infinity.

1

    miR-1

↑↑↑

enriched in sk. muscle 15 ↑pMyo diff. 26 ↑ muscle development 30

↑ C2C12 diff 7 8 10 33 ↑ pMyo diff 33

↑ muscle development 31

↑ muscle development 32

2

miR-15a

↑↑

(this study)

↓ pMyo diff 33

↑ muscle development 31

3

miR-16

(this study)

↓ C2C12 diff 33 ↓ pMyo diff 33

↑ muscle development 31

4

miR-21

↑ pMyo diff. 26

-

↑ muscle development 32

5

miR-22

(this study)

↑ C2C12 diff 33 ↑ pMyo diff 33

↑ muscle development 31

6

miR-23b (n)

(this study)

7

    miR-24

↑pMyo diff. 26

↑pMyo diff, ↑ C2C12 diff 11 33 ↑ C2C12 diff 28 33

enriched in heart 32

8

    miR-26a

↑pMyo diff. 26

↑ C2C12 diff 12 28 ↑ pMyo diff 33

↑ muscle development 32

9

miR-27a

↑pMyo diff. 26

↑ pMyo diff 33

↑ muscle development 31

↓ muscle development 32

10

    miR-27b

(this study)

↑ pMyo 13 33 ↑ C2C12 diff 28 33

11

miR-28 (n)

(this study)

-

12

miR-29a

(this study)

↓ C2C12 diff 28 ↑ C2C12 diff 33

13

miR-30a-5p

↑↑

(this study)

↑ C2C12 diff 28 33

14

miR-30a-3p

(this study)

↑ C2C12 diff 33

15

miR-30c

↑pMyo diff. 26

↑ C2C12 diff 33

↑ muscle development 31

16

miR-30d

↑↑

(this study)

↑ pMyo diff 33

17

miR-30e-3p

(this study)

↑ pMyo diff 33

18

miR-31 (n)

(this study)

19

miR-98 (n)

(this study)

20

miR-99a

(this study)

↑ C2C12 diff 33 ↑ pMyo diff 33

21

miR-101

↑↑

(this study)

-

↑ muscle development 31

22

miR-103 (n)

(this study)

23

miR-107 (n)

(this study)

-

24

miR-126

↑↑

(this study)

↓ C2C12 diff 33

25

miR-128b

↑↑↑

↑ pMyo diff. 27

↑ C2C12 diff 28 ↑ pMyo diff 33

26

    miR-133a

↑↑↑

enriched in sk. muscle 15 ↑pMyo diff. 26 ↑ muscle development 30

↑ C2C12 diff 8 10 33 ↑ pMyo diff 33

↑ muscle development 31

↑ muscle development 32

27

    miR-133b

↑↑↑

enriched in sk. muscle 15 ↑ muscle development 30

↑ C2C12 diff 8 10 ↑ pMyo diff 33

28

miR-140

(this study)

↑ pMyo diff 33

29

miR-152

(this study)

↑ C2C12 diff 28

30

miR-155

↓↓

(this study)

↓ C2C12 diff 34 35 ↓ pMyo diff 33

31

    miR-181b

(this study)

↑ C2C12 diff 16 28 33 ↑ pMyo diff 33

enriched in the heart 32

32

miR-183

(this study)

↓ C2C12 diff 33

33

miR-192

↑↑

(this study)

↑ pMyo diff 33

34

miR-193a (n)

↑↑

(this study)

-

35

miR-204

↓↓

↓ pMyo diff. 27

-

36

    miR-206

↑↑

enriched in sk. muscle 15 ↑ muscle development 30

↑ C2C12 diff 8 10 33 ↑ pMyo diff 33

↑ muscle development

37

miR-210 (n)

(this study)

38

    miR-221

↑pMyo diff. 26 ↓ pMyo diff. 27

↓quail myoblasts diff, ↓ C2C12 diff 29

39

    miR-222

↑pMyo diff. 26 ↓ pMyo diff. 27

↓quail myoblasts diff, ↓ C2C12 diff 29 ↓ C2C12 diff 28

↓ muscle development 32

40

miR-320

(this study)

↑ pMyo diff 33

41

miR-324-3p (n)

↑↑

(this study)

42

miR-324-5p (n)

(this study)

43

miR-331 (n)

(this study)

-

44

miR-339

(this study)

↑ C2C12 diff 33 ↑ pMyo diff 33

45

miR-361

(this study)

↑ pMyo diff 33

46

miR-362

↑↑

(this study)

↑ C2C12 diff 28

47

miR-374 (n)

(this study)

48

miR-432 (n)

(this study)

49

miR-451 (n)

↓↓↓

(this study)

50

miR-452 (n)

↓↓

(this study)

51

miR-500

↑↑

(this study)

↑ C2C12 diff 28 33 ↑ pMyo diff 33

52

miR-501

↑↑↑

(this study)

↑ C2C12 diff 28 33

53

miR-502 (n)

↑↑

(this study)

-

54

    miR-503

(this study)

↑ C2C12 diff 19 28 33 ↑ pMyo diff 33

55

miR-532

↑↑

(this study)

↑ C2C12 diff 28 33 ↑ pMyo diff 33

56

miR-550

↓ pMyo diff. 27

-

57

miR-565 (n)

(this study)

-

58

miR-594 (n)

(this study)

59

miR-659 (n)

↓↓↓

(this study)

-

60

miR-660 (n)

↑↑↑

(this study)

-

microRNAs (MR-miRs) found to be up- and downregulated during myogenic differentiation in this study

To perform transcriptome profiling of myogenic cells, it appears interesting to use primary myogenic cells cultivated in vitro rather than whole muscle tissues. This approach minimizes biases caused by the presence of inflammatory, connective tissue-derived and other non-myogenic cells. Nevertheless, totally avoiding contamination by non-myogenic cells is difficult unless clonal populations of immortalized myogenic cells are used. An alternative to generating immortalized lines of myogenic cells is the utilization of primary cell population enriched for myogenic precursors. However, in previous miRNA and mRNA expression profiling reports, primary skeletal myoblasts cultivated in vitro have not been enriched for myogenic cells prior to analysis.

In the present study, we have thus decided to profile miRNA expression in cultures of CD56+ primary myoblasts and myotubes isolated from healthy individuals using an affinity purification procedure 35 . A total of 60 miRNAs were found to be differentially expressed during myogenic differentiation induced by serum starvation of which 20 had not been previously associated with myogenesis. In addition, we have performed microarray mRNA transcriptome profiling on the same myoblasts and myotubes samples as used for miRNA expression profiling in order to assign targets for these miRNAs.

Results

Identification of new myogenesis-related MIRNA (MRMIRNA) in human primary myoblasts

To identify new myogenesis-related miRNAs in human cells, CD56+ myogenic precursors were isolated from skeletal muscle biopsies of six healthy individuals (Additional file 1). These were then induced to differentiate in vitro using serum starvation and the progression of myogenic differentiation was monitored by following the expression of Myogenin (MYOG) and other myogenic differentiation markers including ID1, TNNT1, TNNT2, MYL4, COL15A1, VIM and CAV1 (Figure 1A). The disappearance of proliferating cells and concomitant emergence of myotubes was monitored using Ki67 staining and microscopic observation (Figure 1B and C).

<p>Additional file 1: Table S1</p>

Samples of myogenic cells used in the study were isolated from six healthy subjects.

Click here for file

<p>Figure 1</p>

Expression of myogenic differentiation markers and miRNA profiling

Expression of myogenic differentiation markers and miRNA profiling. A. Expression of muscle differentiation markers MYOG (myogenin, myogenic factor 4, p-value=0.0016), TNNT1 (Troponin T type 1, skeletal slow, p-value=0.00064), MYL4 (myosine light chain 4, p-value=0.0016), COL15A1 (collagen, type XV, alpha 1, p-value=0.013), TNNT2 (troponin T type 2 (cardiac), p-value=4.8x10^-6), VIM (vimentin, p-value=0.00034), ID1 (inhibitor of DNA binding 1, p-value=1.9x10^-5) and CAV1 (caveolin 1, p-value=0.00015) in proliferating myoblasts (labeled as P) and differentiated myotubes (labeled as D) was measured using qRT-PCR, normalization was performed using ΔΔCt method using GAPDH as a control gene and proliferating sample #1 as a reference sample (expression level 1). The average of three independent experiments is shown. Numbers from 1 to 6 indicate the sample number (for full description refer to Table S1). Insets indicate the average of 6 samples of proliferating myoblasts (P) and differentiated myotubes (D). Asterisk corresponds to p-values<0.05. Error bars correspond to standard deviation (SD) in the case of individual samples and standard error of the mean (SEM) in the case of average expression levels (inset). B. Results of immunofluorescence microscopy analysis of cells stained with anti-Ki67 (red), and anti-Desmin (green) antibodies and DAPI nuclear staining (blue) showing normal cellular localization of these proteins in proliferating myoblasts and differentiated myotubes, 20x magnification. Bar=10 μm. C. The number of Ki67+ cells is significantly reduced during myogenic differentiation in vitro. Results of quantification of the DES+ and Ki67+ cells representing 300 individual cells. Statistically significant difference between cell cultures of proliferating myoblasts and differentiated myotubes is indicated by an asterisk (t-test p-value<0.05).

We observed a statistically significant difference of the expression levels of myogenesis-related markers in proliferating or differentiated myogenic cells isolated from different healthy subjects. This difference was considered as a natural heterogeneity of gene expression levels in different subjects that might be explained by their age, sex, physical activity or diet preferences, therefore, all samples analyzed were included in the study.

The expression of 365 different microRNAs was then profiled in human primary myoblasts and myotubes using TaqMan Low Density Array (TLDA) (Additional file 2). In total, 60 miRNAs were found to be differentially expressed during myogenic differentiation with p-values ranging from 3.4x10-5 to 5x10-2 (Figure 2). These will be referred to as myogenesis-related miRNAs (MR-miRs). Sequences and corresponding TaqMan probe codes for these microRNAs can be found in the Additional file 3.

<p>Additional file 2: Table S2</p>

Results of miRNA expression analysis using TaqMan low density arrays.

Click here for file

<p>Figure 2</p>

miRNA profiling in proliferating myoblasts (left) and differentiated myotubes (right)

miRNA profiling in proliferating myoblasts (left) and differentiated myotubes (right). Out of 365 miRNAs tested, this table shows 60 miRNAs that were differentially expressed in myotubes as compared to myoblasts. Gray levels indicates the expression level of microRNA in each individual sample tested. Labels 1P to 6P correspond to samples of proliferating myoblasts described in Table S1, labels 1D to 6D correspond to the samples of differentiated myotubes described in Additional file 1: Table S1.

<p>Additional file 3: Table S3</p>

Sequences of mature microRNAs and corresponding TaqMan probes used in this study.

Click here for file

The majority (43 out of 60) of MR-miRs were found to be upregulated of which 14 had not been previously reported as involved in the regulation of myogenesis either in humans or in other species (Table 1). Of the 17 MR-miRs that were found to be downregulated during myogenesis, 6 had not been previously associated with myogenic differentiation.

MRNA transcriptome profiling and functional classification of differentially expressed genes

Until now, mRNA expression profiling of human myoblasts has been performed exclusively on primary cells 36 . However, primary skeletal myoblasts have not been enriched for myogenic cells prior to analysis. To avoid analyzing mixed populations of myoblasts and non-myogenic cells, we have used RNA extracted from CD56+ myoblasts purified from muscular tissues. Then, using Agilent transcriptome 44 K microarrays, we identified 6,616 differentially expressed genes of which 3,445 and 3,245 were down- or up-regulated, respectively (Additional file 4). In most cases, a functional class could be assigned to these transcripts using the DAVID Gene Ontology database (Additional file 5) 37 38 .

<p>Additional file 4: Table S4</p>

mRNAs differentially expressed during myogenic differentiation of human primary myoblasts.

Click here for file

<p>Additional file 5: Table S5</p>

Functional classification of genes differentially expressed during myogenic differentiation.

Click here for file

In agreement with previous reports, the majority of upregulated genes were found to control metabolism, myogenesis, insulin receptor signaling or to positively regulate transcription (Table 2). Genes involved in the control of cell cycle, DNA damage response, angiogenesis, cell motility and invasion as well as protein modification and NF-kB signaling belonged to the group of genes downregulated during myogenic differentiation (Table 2). Genes involved in the regulation of ubiquitination/proteolysis, protein transport/localization, transcription regulation and apoptosis were found to be either up- or down-regulated (Table 3). The complete list of genes found to be differentially expressed during in vitro myogenic differentiation of human primary myoblasts can be found in the Additional file 4.

<p>Table 2</p>

    Specific functional classes

Unique genes/cluster

% targets

P-value

FDR

Cluster code

Subclasses are italicized, the cutoff value for differentially expressed genes was set to 1.2 fold change.

    Upregulated

1

Myogenesis

- muscle contraction

81

8,64

3,881E-19

7,23E-16

1_up

- muscle development

145

13,79

6,37E-09

1,19E-05

2_up

- embryonic development

85

11,76

0,0001374

0,255618

3_up

2

Metabolism

- cellular respiration

179

12,85

2,21E-24

4,12E-21

4_up

- phosphate metabolism

217

13,82

2,459E-16

4,11E-13

5_up

- cofactor biosynthesis

57

12,28

5,177E-09

9,64E-06

6_up

- carbohydrate metabolism

50

18,00

1,556E-06

0,002898

7_up

3

Signaling

- insulin receptor signaling

132

19,70

2,61E-07

0,000486

8_up

4

Transcription

- transcription (+) reg

220

15,00

2,624E-07

0,000489

9_up

    Downregulated

1

cell cycle

- cell cycle regulation

285

35,09

1,04E-51

1,95E-48

1_down

- chromosome segregation

42

26,19

2,51E-15

4,77E-12

2_down

- M-phase

31

32,26

3,75E-07

0,000702

3_down

- interphase

34

20,59

2,9E-08

5,43E-05

4_down

- DNA replication

38

34,21

8,04E-06

0,015052

5_down

- centrosome cycle

19

15,79

1,6E-06

0,002987

6_down

2

DNA damage response

- DNA damage response

253

39,53

2,8E-38

5,23E-35

7_down

- telomere maintenance

24

29,17

3,02E-05

0,056435

8_down

3

Wound healing/angiogensis

- wound healing

58

44,83

5,52E-08

0,000103

9_down

- angiogenesis

54

55,56

1,14E-05

0,021416

10_down

4

Cell motility/migration

- cell motility

87

44,83

1,72E-05

0,032183

11_down

5

Protein modification/assembly

- protein glycosylation

36

36,11

0,001102

2,041321

12_down

- protein modification

88

46,59

4,82E-05

0,090071

13_down

6

Metabolism

- nucleotide biosynthesis

84

41,67

5,39E-07

0,001009

14_down

7

Signaling

- response to calcium

40

40,00

2,91E-05

0,054402

15_down

- NF-kB

65

50,77

0,003016

5,494941

16_down

- phosphorylation

163

38,65

3E-07

0,000561

17_down

8

Transcription

- RNA splicing

135

36,30

3,48E-17

6,51E-14

18_down

Specific functional classes of genes differentially expressed during myogenic differentiation

<p>Table 3</p>

Common functional classes

Unique genes/cluster

UP/DOWN

% miRNA targets

P-value

FDR

Subclasses are italicized, the cutoff value for differentially expressed genes was set to 1.2 fold change.

1

Protein modification/assembly

ubiquitination/proteolysis

305

UP

16,07

4,118E-23

7,67E-20

10_up

162

DOWN

39,51

2,97E-05

0,055652

19_down

protein complex assembly

131

UP

9,16

0,0001135

0,21125

11_up

177

DOWN

30,51

7,01E-17

2,11E-13

20_down

2

Transport/localization

transport/localization

243

UP

16,05

1,299E-17

2,42E-14

12_up

279

DOWN

41,22

1,27E-11

2,39E-08

21_down

3

Transcription

transcription regulation

458

UP

13,32

7,64E-10

1,42E-06

13_up

36

DOWN

41,67

0,000311

0,57965

22_down

transcription (-) reg,

148

UP

11,49

9,994E-07

0,001862

14_up

203

DOWN

36,45

1,19E-09

2,23E-06

23_down

chromatin organization/modification

86

UP

9,30

0,0005777

1,070598

15_up

153

DOWN

30,72

5,88E-23

1,1E-19

24_down

4

Apoptosis

apoptosis

216

UP

17,59

8,615E-07

0,001605

16_up

216

DOWN

38,43

1,26E-08

2,36E-05

25_down

5

Signaling

reg, of kinase activity

204

UP

15,69

1,362E-06

0,002537

17_up

233

DOWN

40,77

2,22E-06

0,00416

26_down

6

Cell morphogenesis

cytoskeleton organization

130

UP

14,62

0,0002361

0,438978

18, 19_up

193

DOWN

35,23

1,05E-17

1,96E-14

27_down

Common functional classes unifying genes up- and downregulated during myogenic differentiation

Predication of myogenesis-related MIRNA target genes

A common practice to boost target gene predictions accuracy is to use several prediction algorithms and then to combine their predictions. However, this approach has been proved inefficient 39 . Therefore, we have used a single algorithm, e.g. RNA22 40 to predict miRNA targets. RNA22 has been chosen for its low rate of false-positive predictions as compared to other algorithms 39 . For each miRNA, the number of target predictions varied between 261 and 3,058.

According to previous reports, the proportion of correct predictions can be as low as 10% 41 42 (for recent review see 43 . To increase the accuracy of bioinformatic predictions, we used a simultaneous mRNA/miRNA expression profiling approach described in 42 44 45 . Based on the fact that MiRNA regulate gene expression by inhibiting translation or inducing deadenylation of mRNAs followed by their degradation (for review see 46 47 ), we reasoned that the expression levels of mRNA and miRNA should be inversely correlated if one regulates the other. Indeed, for upregulated MR-miRNA, the majority of their predicted target genes was found to be underexpressed. Similarly, most downregulated MR-miRNAs had upregulated predicted targets. Indeed, for every microRNA tested, the distribution of Pearson correlation coefficients of its predicted target genes was shifted towards negative values. This was the case neither for randomly selected genes, nor when the sample correspondence was permuted (Figure 3A and the Additional file 6) which was used to establish a significance threshold of Pearson correlation coefficients. Target genes with correlation coefficients below the threshold had less than 5% chances to be random. We call these genes “supported targets” to underscore the fact that the prediction was supported by mRNA transcriptome profiling (Additional file 7). On average, 11% of microRNA target genes predicted by the RNA22 algorithm were “supported” by mRNA transcriptome profiling (Figure 3B).

<p>Figure 3</p>

Bioinformatic predictions of microRNA target genes

Bioinformatic predictions of microRNA target genes. A. Density plot of Pearson correlation coefficients between expression of miRNA and their target genes (continuous line) predicted by RNA22 algorithm. Number of genes is expressed as% of total predictions indicated within each plot. The distribution of Pearson correlations is clearly shifted towards negative values; the density plot of Pearson correlation coefficient after permutation of the list of microRNAs (dashed line). In this case the distribution is centered around zero. Several examples are shown, for other microRNAs see the Additional file 6. B. Diagram showing the proportion of bioinformatic predictions made by RNA22 algorithm (taken for 100%) that were supported by transcriptome profiling (black). Light grey shows unsupported predictions. The graphs corresponding to TargetScan predictions are presented in the Additional file 8. C. Comparison of the accuracy of target gene predictions by RNA22 and TargetScan algorithms.% of target genes predicted by both algorithms and supported by transcriptome data is shown.

<p>Additional file 6: Figure S1</p>

A. Density plot of Pearson correlation coefficients between expression of miRNA and their target genes (continuous line) predicted by RNA22 algorithm and the the density plot of Pearson correlation coefficient after permutation of the list of microRNAs (dashed line). B. Schematic representation of ectopic overexpression/knockdown of miRNA in the cells that served to confirm their targets genes supported by transcriptome data.

Click here for file

<p>Additional file 7: Table S6</p>

Target genes of microRNAs differentially expressed during myogenic differentiation, supported by transcriptome analysis of mRNA expression.

Click here for file

We then compared the accuracy of predictions made by RNA22 and TargetScan, another popular miRNA target prediction algorithm. As an indication of accuracy, we have used a percentage of predicted targets that were supported by transcriptome data. For 11 of 17 target genes, RNA22 demonstrated higher percentage of predictions supported by transcriptome data, for 2 more microRNAs the difference in the accuracy of predictions was insignificant (Figure 3C and Additional file 8).

<p>Additional file 8: Figure S2A</p>

Density plot of Pearson correlation coefficients between expression of miRNA and their target genes (blue) predicted by TargetScan algorithm and the density plot of Pearson correlation coefficient after permutation of the list of microRNAs (red). B. Diagram showing the proportion of bioinformatic predictions made by TargetScan algorithm (taken for 100%) that were supported by transcriptome profiling (black). Blue bars show unsupported predictions.

Click here for file

QRT-PCR validation of supported MIRNA target genes

To demonstrate the relevance of our miRNA target predictions, we altered the expression of several microRNAs and measured the expression of their predicted target genes, supported by the transcriptome data. To illustrate the impact of miRNA repression on the expression of their target genes, we have chosen to inhibit the expression of four well-characterized myogenic microRNAs miR-1, -133a, -133b and -206 in human immortalized myoblasts using LNA (Locked Nucleic Acids) antisense microRNAs (anti-miRs). Human immortalized myoblasts were differentiated in vitro and then transfected separately with anti-miRs targeting miR-1, miR-133a, miR-133b and miR-206. miR-1 and miR-206 have the same seed sequence and, therefore, target very similar lists of genes. The same is true for miR-133a and miR-133b. We have then randomly selected 12 and 10 genes predicted to be targeted by miR-1/206 and miR-133a/b respectively and supported by our transcriptome data and tested their expression using qRT-PCR in the cells transfected with corresponding anti-miRs. Repressing miR-1/206 resulted in the upregulation of six of its targets: AP3D1 (adaptor-related proteins complex 3, delta 1 subunit), COL3A1 (collagen, type III, alpha 1), HDAC1 (histone deacetylase 1), PDCD4 (programmed cell death 4), PRKAB2 (protein kinase, AMP-activated beta 2 non-catalytic subunit) and ZNF365 (zinc finger protein 365). These target genes were considered as novel “qRT-PCR validated” target genes of miR-1 and -206 (Figures 4A). Six other target genes supported by our transcriptome data including ATP2B1, C11orf45, FOXP, G2E3, MBOAT7 and TUBB could not be validated via qRT-PCR experimentally, as we did not observe significant changes of their expression following anti-miR transfection (data not shown).

<p>Figure 4</p>

Confirmation of bioinformatic predictions of miR targets

Confirmation of bioinformatic predictions of miR targets. Human immortalized myoblasts (iMyo) cultivated in growth medium (P) or differentiation medium for 3 days (D) were transfected with either control LNA (anti-miR-C) or LNA against miR-1 and miR-206, miR-133a and miR-133b (A). Human rhabdomyosarcoma cells (RD) were transfected with plasmids coding for miR-128 and miR-30 precursors or scrambled sequence (scr) (B). Then the expression of corresponding microRNA and their randomly selected target genes was tested using qRT-PCR, normalization was performed using ΔΔCt method using GAPDH as a control gene and proliferating sample #1 as a reference sample (expression level 1). Transcriptome-supported target genes of miR-1/206 (C) and miR-133a/b (D) were downregulated during normal myogenic differentiation but not when it was accompanied by the transfection with corresponding anti-miRs. Transcriptome-supported target genes of miR-128 and miR-30 were downregulated when human rhabdomyosarcoma cells were transfected with lentiviral constructs overexpressing miR-128 (E) and miR-30 (F). The average of three independent experiments is shown. (*) indicates p-value <0.05; (G): Diagram showing the proportion of supported predictions that were qRT-PCR validated in this study. Black: validated targets, gray: non-validated targets.

In the case of miR-133a and -133b, immortalized myotube transfection anti-miRs resulted in the upregulation of six of ten randomly selected target genes, supported by our transcriptome data. These novel qRT-PCR validated targets of miR-133a and -133b include ASAP2 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 2), ARFGAP1 (ADP-ribosylation factor GTPase activating protein 1), ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide), C7orf51 (chromosome 7 open reading frame 51), RBM15B (RNA binding motif protein 15B) and TMCC2 (transmembrane and coiled-coil domain family 2) (Figures 4B). Four other target genes supported by our transcriptome data including LMCD1, NAT9, PRPF38A and SYNGR2 could not be validated via qRT-PCR, as we did not observed significant changes of their expression following anti-miR transfection (data not shown).

To illustrate the impact of miRNA overexpression on the expression of their target genes, we have selected two microRNAs, miR-30 and -128, that were previously shown to be upregulated during myogenic differentiation 26 27 , but their function in myogenesis is not well-established. Two plasmids coding for the corresponding pre-miRNAs or scrambled sequence were transfected separately into human rhabdomyosarcoma cells, and the expression of their target genes was then tested via qRT-PCR. Ectopic overexpression of miR-128 led to the downregulation of three of its four target genes, randomly selected among the genes supported by our transcriptome data. These novel qRT-PCR validated miR-128 target genes include EDARADD (EDAR-associated death domain), CAV1 (Caveolin 1) and DTYMK (deoxythymidylate kinase) (Figures 4C). One transcriptome-supported miR-128 target gene, RBM15B, could not be validated using qRT-PCR, as we did not observed significant changes in its expression level following miRNA precursor tranfection (data not shown).

Similarly, overexpressing miR-30 led to the downregulation of three of its five randomly selected transcriptome-supported targets. These qRT-PCR validated miR-30 targets include PLXNB (plexin B2), C11orf45 (chromosome 11 open reading frame 45) and ATP2B1 (ATPase, Ca++ transporting, plasma membrane 1) (Figures 4D). Two remaining miR-30 target genes, PPIA and CASD1 could not be validated via qRT-PCR, as we did not observed significant changes in its expression level following miRNA precursor transfection (data not shown).

Overall, at least 50% of the supported target genes tested in this study appeared to be regulated by their corresponding microRNA either directly or indirectly which is significantly better than the result of ordinary bioinformatic prediction with only 10% of correctly predicted target genes.

Functional analysis of MR-MIRNA target genes supported by transcrptome data

After functional classification of genes differentially expressed during myogenic differentiation in vitro, we thought to determine the proportion of microRNA-controlled genes within each functional class. Almost 30% of all protein coding genes contain miRNA seeds in their 3UTRs and are, therefore, potential miRNA targets 48 . Indeed, we have found that a significant proportion of genes differentially expressed during myogenic differentiation appeared to be controlled by microRNAs. However, the proportion of genes targeted by microRNAs was not the same within different functional classes. For example, 50% to 55% of genes related to angiogenesis and NF-kB signaling were potentially targeted by miRNAs, while in the case of myogenesis, potential miRNA targets represented only 8.6% of genes (Table 2). Interestingly, more miRNA targets were found among downregulated than upregulated genes. For example, among apoptosis-related genes, 17.6% of upregulated and 38.4% of downregulated genes were found to be targeted by miRNAs (Table 3). This observation prompted us to search for known functions of each supported target gene of every MR-miRNA described in this study using DAVID functional annotation tool 37 38 .

miR-1 and miR-206

It has been previously demonstrated that miR-1 and -206 target genes linked to the regulation of chromatin modifications 8 , transcription 20 49 and cell cycle 50 . Functional analysis of predicted miR-1 target genes supported by transcriptome data indicated that these microRNAs might also target genes involved in the regulation of apoptosis, DNA damage response, cell motility and protein modification, cell signaling and kinase activity 33 . Our own functional analysis of predicted target genes of miR-1 and -206 supported by transcriptome analysis confirmed that miR-1 and miR-206 might target genes involved in in these biological processes. In addition, miRNA-1 and -206 might target genes implicated in cytoskeleton organization, ubiquitination and nucleotide biosynthesis (Figure 5, Additional file 9).

<p>Figure 5</p>

Predicted functions of MR-miRs

Predicted functions of MR-miRs. Green: functions downregulated during myogenic differentiation, Red: functions upregulated during myogenic differentiation. Yellow: functions that are both up- and downregulated during myogenic differentiation. Framed are the functions that have not been previously ascribed to a given microRNA.

<p>Additional file 9: Table S8</p>

Functions of miRNA target genes supported by transcriptome data. Functional classification has been performed using DAVID functional annotation tool.

Click here for file

miR-21

It has been demonstrated that miR-21 targets genes involved in in apoptosis 51 52 and regulation of kinase activity 53 54 55 56 and regulation of gene expression 57 . Here we confirm that miR-21 might target genes involved in these biological processes and might also target genes involved in transport, cell cycle regulation, chromatin assembly, protein modification, NF-kB signaling, protein complex assembly and DNA damage (Figure 5, Additional file 9).

miR-24

It has been demonstrated that miR-24 is involved in DNA damage response 58 59 , regulation of cell cycle progression 59 60 , regulation of kinase activity and protein phosphorylation 61 , transcription 62 and apoptosis 63 . We confirm that miR-24 might control genes implicated in these biological processes. In addition, miR-24 might control genes implicated in the regulation of transport , NF-kB signaling, protein ubiquitination and complex assembly, RNA splicing and chromatin modification (Figure 5, Additional file 9).

miR-26a

It has been previously demonstrated that miR-26a target genes are implicated in cell cycle control 64 , apoptosis 65 , regulation of kinase activity and protein phosphorylation 66 , as well as chromatin modification 12 . Here we confirm that miR-26a might target genes involved in the regulation of cell cycle, apoptosis, kinase activity and protein phosphorylation, but not in chromatin modification. In addition, miR-26a might target genes involved in the regulation of transport, DNA damage response, protein modification and protein complex assembly, as well as nucleotide biosynthesis and RNA splicing (Figure 5, Additional file 9).

miR-27a

miR-27b is involved in the regulation of transcription by inhibiting the expression of various transcription factors 13 67 68 69 70 . Here we confirm the role of miR-27b as an important transcriptional regulator, in addition, our predictions suggest that miR-27a might be involved in the regulation of intracellular transport, apoptosis, kinase activity, protein complex assembly, cytoskeleton organization and other biological functions including DNA damage response, cell cycle, motility, nucleotide biosynthesis and protein phosphorylation (Figure 5, Additional file 9).

miR-30c

miR-30 was shown to induce apoptosis 71 and regulate cell motility by influencing extracellular the matrix remodelling process 72 73 74 . This microRNA is also known to regulate protein modification e.g. sumoylation 75 and transcription 72 73 76 77 . We here confirm that miR-30c might target genes participate in the regulation of apoptosis and cell motility regulation but not transcription control. Instead, our predictions suggest that miR-30 might target genes involved in the regulation of protein phosphorylation and kinase activity, cell cycle control, intracellular transport, cytoskeleton organization, protein ubiquitination, DNA damage response and nucleotide biosynthesis (Figure 5, Additional file 9).

miR-128b

It has been previously demonstrated that miR-128b targets genes involved in the regulation of cell cycle 78 79 , transcription 78 79 and apoptosis 79 80 . In addition, transcriptome analysis of cell transfected with miR-128 revealed an alteration of the expression of genes implicated in cytoskeleton organization, kinase activity and protein phosphorylation 81 . Here we confirm the target genes of miR-128 might be involved in these biological functions. In addition, our predictions suggest that miR-128 might target genes in DNA damage response, transport, protein modification and ubiquitination and cell motility (Figure 5, Additional file 9).

miR-133a and miR-133b

Previously, these microRNAs have been shown to control genes involved in the regulation of transcription 8 82 , cytoskeleton structure 83 84 85 86 87 , apoptosis 88 and mRNA splicing 89 . Here we confirm that miR-133a/b might target genes involved in these biological functions. In addition, miR-133a/b might target genes involved in intracellular transport, cell cycle regulation, DNA damage response, protein phosphorylation and ubiquitination (Figure 5, Additional file 9).

miR-204

It has been previously shown that miR-204 is involved in the regulation of transcription 90 91 92 , controls cell migration cytoskeleton organization 92 93 94 . miR-204 has been also shown to be involved in regulation of apoptosis by targeting multiple genes 95 and in the regulation of cell signaling 94 , 96 . Here we confirm that miR-204 might target genes involved in transcription regulation, cytoskeleton organization and apoptosis but not cell signaling and cell migration. Furthermore, our predictions suggest that this microRNA might target genes involved in the control of ubiquitination, cellular respiration and intracellular transport (Figure 5, Additional file 9).

miR-221 and miR-222

Previously, these microRNAs have been show to target genes involved in the process of protein degradation 97 , apoptosis 98 , kinase activity 99 100 , cell cycle progression 29 and cell motility 101 . We here confirm that miR-221 and -222 might target genes involved in protein degradation (via ubiquitination), apoptosis, and kinase activity regulation, but not cell cycle progression or cell motility. In addition, miR-221 and -222 might also target genes that play a role in the regulation of transcription, insulin signaling, intracellular transport and cellular respiration (Figure 5, Additional file 9).

miR-550

No target genes and functions of this microRNA were not previously described. Our predictions suggest that miR-550 might target genes involved in the regulation of transcription, protein ubiquitination, phosphate metabolism, apoptosis, insulin signaling, muscle development, intracellular transport and cellular morphology (Figure 5, Additional file 9).

The full list of supported target genes of MR-miRs with and without assigned functions can be found in the Additional file 7.

Discussion and conclusion

MicroRNAs, particularly miR-1, -206 and -133a/b, play crucial roles in myogenesis 6 . These are called MyomiRs to underscore their importance in myogenesis (for review see 24 ). Previously, high-throughput profiling of miRNA expression performed in human myoblasts have resulted in identification of miRNAs differentially expressed during myogenic differentiation 26 27 . Besides that, a larger number of miRNAs have been found to be differentially expressed during myogenic differentiation of mouse C2C12 myoblasts 19 28 , mouse myogenic progenitors 18 21 or at various stages of development of skeletal muscles in pig 31 or in the common carp 32 .

Here, we have compared miRNA expression profiles in human proliferating primary CD56+ myoblasts and differentiated myotubes. Sixty differentially expressed miRNAs were identified (MR-miRs). Twenty of these had not been previously implicated in myogenesis. Conversely, several miRNAs previously reported as related to myogenic differentiation were not identified in the present study. These included miR-214 18 , hsa-miR-424 (identical to mmu-miR-322) 19 , miR-29b/c 14 , miR-143, miR-208a 15 , miR-208b, miR-499 17 , miR-125b 102 (Additional file 10). One miRNA, miR-682, previously shown to be upregulated in mouse myogenic precursors 21 could not be tested here. The difficulties to confirm previously reported data for several miRNAs associated with myogenesis in model organisms could be due to species-specific characteristics in the myogenesis program or could originate from differences in experimental conditions. Indeed, high-throughput miRNA expression profiling has been previously performed using mixed cell populations isolated from skeletal myoblasts 26 27 . The resulting presence of non-myogenic cells, including fibroblasts and inflammatory cells, could have altered the resulting miRNA expression profiles. It thus appears that the existing repertoire of myogenic miRNAs is still incomplete or contaminated with miRNAs unrelated to myogenesis. For example, we have demonstrated that miR-221 and miR-222 were downregulated during myogenic differentiation of human myoblasts while others reported their upregulation 26 . Our results are in agreement with previous reports demonstrating that these microRNAs are downregulated during myogenesis in mice 28 29 .

<p>Additional file 10: Table S7</p>

microRNAs that were previously shown to be differentially expressed during myogenesis but could not be confirmed in the present study.

Click here for file

In addition to microRNA expression profiling, we have profiled mRNA expression in myogenic cells in the course of myogenic differentiation. Transcriptome analysis of myogenesis has been previously reported by others. In mice, several models have been used for transcriptome profiling. These include C2C12 immortalized cell line considered as the “golden standard” of in vitro myogenic differentiation 103 104 105 106 107 , primary mouse myoblasts 108 and an in vivo model of muscle regeneration following injury 109 . In humans, the only published mRNA expression profiling has been performed on primary cells grown in vitro 36 . The transcriptome profiling of human myoblasts in the course of myogenic differentiation in vitro described here, has two important advantages over the previously published study. Firstly, we used CD56+ myogenic cells that allowed us to exclude from the analysis genes unrelated to myogenesis. Secondly, our study is the first example of a simultaneous miRNA/mRNA expression profiling of myogenic cells.

Simultaneous miRNA/mRNA was used here to identify novel target genes of myogenesis-related microRNAs. This approach has been proven efficient for increasing the precision of bioinformatics predictions for miRNA targets 42 , and it has been applied previously to identify miRNA target genes in neural tissue 45 and cancer cell lines 44 110 , but not in myogenic cells or muscle tissue.

Several methods are used to validate the target genes of miRNA. These include qRT-PCR, luciferase assays and western blot (for review see 111 and 112 ). Luciferase assay based on a reporter plasmid containing miRNA recognition sites in the 3 UTR of the luciferase gene is the method used to demonstrate the direct inhibition of mRNA expression by miRNA. However this method does not provide information as to whether the miRNA-dependent regulation occurs at the level of transcript stability or at the level of translation, nor the direct miRNA:mRNA interaction demonstrated by this method does guarantee the physiological significance of the observed miRNA effect. Here, to validate the predicted target genes, we have used qRT-PCR validation approach. This method is more physiological than luciferase assay as it measures the expression of target gene from their natural genomic context, although it can not discriminate between direct and indirect effects of miRNA expression. Hereby, we have randomly selected 32 genes targeted by 6 different microRNAs including miR-1, -206, -133a, -133b, -128 and -30 and tested their expression using pRT-PCR in the cells where corresponding microRNA was ectopically overexpressed or inhibited. We have demonstrated the miRNA-dependent inhibition for 18 of these target genes. We called these genes “qRT-PCR validated” to formally distinguish them from simply “validated”, as the latter term is usually reserved for miRNA target genes validated using luciferase reporters.

On average, we estimate that the lists of predicted target genes supported by transcriptome data contain at least 50% of genes that will change their expression, according to our predictions, in response to the alterations of microRNA expression.

Using the lists of target genes supported by transcriptome data we have deduced functional impact of MR-miRs using DAVID functional annotation tool 37 38 . Our predictions generally corresponded to already known functions of MR-miRs demonstrated by others, but also allowed us to make suggestions about novel functions of MR-miRs. It has to be noted, that these predictions have to be handled with caution for two reasons: (i) according to our estimation, among target genes supported by transcriptome analysis, up to 50% might not react to miRNA alteration, as predicted; (ii) the functions of MR-miR have been deduced using bioinformatic prediction algorithms that can not substitute for a true experimental validation of microRNA functions.

To summarize, we have discovered 20 human miRNAs not previously known to be differentially expressed during myogenic differentiation and confirmed 40 myogenesis-related microRNAs. We then used an approach that included a simultaneous miRNA/mRNA expression profiling to predict targets genes of these microRNAs with more than 50% accuracy, although whether these are direct or indirect targets of miRNA remains unknown. Finally, we deduced novel functions of these microRNA from the known functions of their target genes. Further studies are necessary to confirm our predictions of functional contribution of newly discovered miRNAs to the process of myogenic differentiation.

Methods

Cell culture conditions and transfection

Primary human myoblasts were isolated from skeletal muscles of healthy subjects as described in 35 , for details see Additional file 4: Table S4), purified with an immuno-magnetic sorting system (Miltenyi Biotec, USA) using an anti-CD56/NCAM antibody according to the manufacturer’s instructions. CD56-positive myoblasts were seeded in collagen-coated Petri dishes (P1) and cultured in DMEM, 10% FCS, 1% Ultroser G, at 37°C with 5% CO2.All experiments were carried out between P1 and P5 to avoid cell senescence. Myoblast purity was determined by staining for Desmin. Purified myoblasts were plated in collagen-coated Petri dishes and cultured in growth medium containing DMEM supplemented with 20% fetal bovine serum at 37°C in humidified atmosphere with 5% CO2. Myogenic differentiation of confluent cells was induced after 5 days by changing to DMEM containing 2% FBS (differentiation medium). Cells were kept in differentiation medium for 3 days. Myogenic fusion index at day three was 37-70%. Human immortalized myoblasts (iMyo) (kind gift of Dr. V. Mouly) were grown and differentiated as described in 113 . RD and TE671 (a kind gift of Dr. S. Leibowitz) were grown as described 114 . phrGFP-1 vector was from Stratagen, pcDNA3.2/V5 hsa-mir-128 (#26308) 115 and pCMV-miR30 (#20875) 116 vectors were provided by Addgene. Transient transfection of RD cells was performed in 6-well plate format using Lipofectamine 2000 according to manufacturer’s instructions with minor modification: 600.000 cells were added to the transfection mixture prepared directly in the cell culture plate. To transfect human immortallized myoblasts, anti-sense LNA inhibitors of miR-1, -206, 133a and b, and the irrelevant control were purchased from Exiqon (Denmark) and were mixed with LipoRNAiMAX (Invitrogen) in 6-well plates at 100nM final concentration, using 500 000 cells per well.

Reverse transcription and real-time PCR

For microRNA expression analysis 400 ng of total RNA purified via Trizol (Invitrogen) was converted into cDNA using 8 independent pools of primers (#4384791, Applied Biosystems, AB) and TaqMan microRNA Reverse transcription kit (#4366596, AB). cDNA was quantified using via qPCR using TaqMan 2x Universal PCR Master Mix, No AmpErase UNG (#4324018, AB) and human microRNA panel version 1.0 TLDA (TaqMan Low Density Array, AB), data were acquired on AB7900HT Real-Time PCR machine. Sequences of microRNAs and corresponding codes of TaqMan assays can be found in Additional file 2. For mRNA expression analysis total RNA was isolated from 2x106 proliferating myoblasts, or differentiated myotubes using Trizol (Invitrogen) and reverse transcribed using the High Capacity cDNA Archive kit (Applied Biosystems, AB) according to the manufacturer protocol. cDNA was mixed with 2x Taqman PCR mix (AB) and amplified customized TLDA (TaqMan Low Density Array) using Abiprism 7900HT apparatus (AB). In case of miRNA and mRNA the expression level was calculated from Ct values using ΔΔCt method using GAPDH as a control 117 . The calculation of SEM in case of average of multiple samples has been done as described in 118 .

Transcriptome profiling and data processing

Human primary myoblasts were sacrificed directly on plates at 30% confluency using Trizol, RNA was prepared using organic extraction and ethanol precipitation as described 119 followed by silica column cleanup on silica columns (Nucleospin RNA Extraction kit, Macherey Nagel). RNA extracted from individual myoblast lines was Cy5-labeled, mixed with with a pool of RNA samples labeled with Cy3 and hybridized to Gene Expression microarrays (4x44k #G4112F Agilent) and scanned as instructed by the manufacturer. Scanned images were then analysed using the Feature Extraction Software (Agilent), the subsequent gene expression data treatment was performed using R and Bioconductor. Spots with intensity lower than 50 or lower than background in more than 50% of biological replicates have been removed from further analysis. The background correction and intensity normalization procedures were applied for the remaining ~30 000 probes using the Bioconductor package vsn 120 . A background offset and a scaling factor for each array and dye channel were calculated using the least squares regression procedure, then the generalized log-transformation was applied. The ordinary least squares regression approach is based on the assumption that “most genes are not differentially expressed”. However, in the case of myogenic differentiation, where many genes are differentially expressed, this assumption does not hold. Therefore, to apply the above mentioned approach to myogenic differentiation, the vsn least squares model has first been applied to a subset of features, and then extended for the whole set of features. To select the subset of features, a pool of samples prepared from five different proliferating myoblast lines before and after myogenic differentiation were hybridized to two additional microarrays. Then 14.358 features that did not exceed the cutoff value of 1.23 fold change between the pools have been selected. To determine the differentially expressed genes, a t-test analysis was conducted using the limma package from Bioconductor 120 . Using this package, a linear model is fitted to the expression data for each gene. An empirical Bayes moderation of the standard errors were performed. This method borrows information across genes in order to arrive at more stable estimates of each individual gene’s variance, even for experiments with small number of arrays. The microarray data related to this paper have been submitted to the Array Express data repository at the European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress) under the accession number E-MTAB-1577 (release date 2014-3-22).

miRNA targets predictions

RNA22 40 and TargetScan algorithms 121 have been used to predict miRNA target genes in this study. miRNA targets identified by RNA22 have been downloaded from the RNA22 website http://cbcsrv.watson.ibm.com/rna22.html. Predictions were processed in the form of 3 UTR binding sites occurrence matrices, containing the number of 3UTR binding sites for each combination of miRNA (columns) and mRNA (rows).

Pearson correlation between mRNA and miRNA expression profiles and permutation tests for significance

All the following has been performed using the R software. Pearson correlation values were computed using expression levels of each single transcript available and for each miRNA, found to be differentially expressed during myogenic differentiation in this study. Pearson correlation values were retained for further analysis, if they were corresponding to miRNA and mRNA pares having at least one occurrence in at least one of the two 3UTR binding sites occurrence matrices. To distinguish between biologically significant and random correlations, we performed a permutation test. We performed nine different permutations by calculating correlation values using a miRNA table with permuted sample designations. Then, the distribution of the real and permuted data were graphically plotted. For each miRNA, the 5% percentile of the Pearson correlation obtained with the permuted data was used as a threshold (th) for selecting biologically significant target genes. For each differentially expressed miRNA, the Pearson correlation value is compared to th and if smaller, the gene is retained as a biologically significant target gene regulated by the miRNA, with a 5% risk of error.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

YSV and PDm designed the experiments, PDm, AP, TR, TAW, VL, AT, GC and DL-C performed the experiments, PDm, AB, MO’C and PDe conducted bioinformatic analysis of the data, YSV, PDm and ML wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by grants from the Association Française contre les Myopathies (AFM) to YSV and DL PD is co-funded by the University Montpellier I and the association “Amis FSH”.

<p>Genomics of microRNA</p>KimVNNamJWTrends Genet2006223165173<p>Genomic organization of microRNAs</p>OlenaAFPattonJGJ Cell Physiol20102223540545<p>Control of translation and mRNA degradation by miRNAs and siRNAs</p>Valencia-SanchezMALiuJHannonGJParkerRGenes Dev2006205515524<p>Switching from repression to activation: microRNAs can up-regulate translation</p>VasudevanSTongYSteitzJAScience (New York, NY2007318585819311934<p>Muscling through the microRNA world</p>CallisTEDengZChenJFWangDZExperimental biology and medicine (Maywood, NJ20082332131138<p>MicroRNA-206: the skeletal muscle-specific myomiR</p>McCarthyJJBiochim Biophys Acta2008177911682691<p>Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis</p>ZhaoYSamalESrivastavaDNature20054367048214220<p>The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation</p>ChenJFMandelEMThomsonJMWuQCallisTEHammondSMConlonFLWangDZNat Genet2006382228233<p>MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease</p>Townley-TilsonWHCallisTEWangDInt J Biochem Cell Biol200942812521255<p>Myogenic factors that regulate expression of muscle-specific microRNAs</p>RaoPKKumarRMFarkhondehMBaskervilleSLodishHFProc Natl Acad Sci USA20061032387218726<p>Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation</p>SunQZhangYYangGChenXZhangYCaoGWangJSunYZhangPFanMNucleic Acids Res200836826902699<p>MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis</p>WongCFTellamRLJ Biol Chem20082831598369843<p>Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression</p>CristCGMontarrasDPallafacchinaGRocancourtDCumanoAConwaySJBuckinghamMProc Natl Acad Sci USA2009106321338313387<p>NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma</p>WangHGarzonRSunHLadnerKJSinghRDahlmanJChengAHallBMQualmanSJChandlerDSCancer Cell2008145369381<p>Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation</p>SempereLFFreemantleSPitha-RoweIMossEDmitrovskyEAmbrosVGenome Biol200453R13<p>The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation</p>NaguibnevaIAmeyar-ZazouaMPolesskayaAAit-Si-AliSGroismanRSouidiMCuvellierSHarel-BellanANat Cell Biol200683278284<p>A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance</p>van RooijEQuiatDJohnsonBASutherlandLBQiXRichardsonJAKelmRJJrOlsonENDev Cell2009175662673<p>Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells</p>JuanAHKumarRMMarxJGYoungRASartorelliVMol Cell20093616174<p>MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A</p>SarkarSDeyBKDuttaAMol Biol Cell2010211321382149<p>miR-206 and -486 induce myoblast differentiation by downregulating Pax7</p>DeyBKGaganJDuttaAMol Cell Biol2011311203214<p>Temporal MicroRNA Expression during in vitro Myogenic Progenitor Cell Proliferation and Differentiation: Regulation of Proliferation by miR-682</p>ChenYGelfondJMcManusLMShiremanPKPhysiol Genomics201143621630<p>IGF-II is regulated by microRNA-125b in skeletal myogenesis</p>GeYSunYChenJJ Cell Biol201119216981<p>Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation</p>le SageCNagelREganDASchrierMMesmanEMangiolaAAnileCMairaGMercatelliNCiafreSAEMBO J2007261536993708<p>MicroRNAs in skeletal myogenesis</p>GeYChenJCell cycle (Georgetown, Tex2011103441448<p>MicroRNAs in skeletal muscle: their role and regulation in development, disease and function</p>GullerIRussellAPJ Physiol2010588Pt 2140754087<p>Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma</p>CiarapicaRRussoGVerginelliFRaimondiLDonfrancescoARotaRGiordanoACell cycle (Georgetown, Tex200981172175<p>The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway</p>GranjonAGustinMPRieussetJLefaiEMeugnierEGullerICeruttiCPaultreCDisseERabasa-LhoretRDiabetes2009581125552564<p>Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis</p>SunYGeYDrnevichJZhaoYBandMChenJJ Cell Biol2010189711571169<p>Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal muscle cells</p>CardinaliBCastellaniLFasanaroPBassoAAlemaSMartelliFFalconeGPLoS One2009410e7607<p>Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle</p>KoutsoulidouAMastroyiannopoulosNPFurlingDUneyJBPhylactouLABMC Dev Biol20111134<p>MicroRNA expression profiles of porcine skeletal muscle</p>ZhouBLiuHLShiFXWangJYAnim Genet2010415499508<p>Identification and profiling of microRNAs from skeletal muscle of the common carp</p>YanXDingLLiYZhangXLiangYSunXTengCBPLoS One201271e30925<p>Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation</p>MarziMJPuggioniEMDall’OlioVBucciGBernardLBianchiFCrescenziMDi FiorePPNicassioFJ Cell Biol201219917795<p>miR-155 inhibits expression of the MEF2A protein to repress skeletal muscle differentiation</p>SeokHYTatsuguchiMCallisTEHeAPuWTWangDZJ Biol Chem2011286413533935346<p>Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects</p>BarroMCarnacGFlavierSMercierJVassetzkyYLaoudj-ChenivesseDJ Cell Mol Med2010141–2275289<p>Large-scale gene expression analysis of human skeletal myoblast differentiation</p>SterrenburgETurkRHoen PATVan DeutekomJCBoerJMVan OmmenGJDen DunnenJTNeuromuscul Disord2004148–9507518<p>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</p>da HuangWShermanBTLempickiRANat Protoc2009414457<p>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</p>da HuangWShermanBTLempickiRANucleic Acids Res2009371113<p>Predicting microRNA targets and functions: traps for the unwary</p>RitchieWFlamantSRaskoJENat Methods200966397398<p>A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes</p>MirandaKCHuynhTTayYAngYSTamWLThomsonAMLimBRigoutsosICell2006126612031217<p>Lost in translation: an assessment and perspective for computational microRNA target identification</p>AlexiouPMaragkakisMPapadopoulosGLReczkoMHatzigeorgiouAGBioinformatics2009252330493055<p>Using expression profiling data to identify human microRNA targets</p>HuangJCBabakTCorsonTWChuaGKhanSGallieBLHughesTRBlencoweBJFreyBJMorrisQDNat Methods200741210451049<p>A study of miRNAs targets prediction and experimental validation</p>HuangYZouQSongHSongFWangLZhangGShenXProtein Cell2010111979986<p>Correlation of expression profiles between microRNAs and mRNA targets using NCI-60 data</p>WangYPLiKBBMC Genomics200910218<p>Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation</p>Nunez-IglesiasJLiuCCMorganTEFinchCEZhouXJPLoS One201052e8898<p>MicroRNAs in development and disease</p>SayedDAbdellatifMPhysiol Rev2011913827887<p>MicroRNAs: target recognition and regulatory functions</p>BartelDPCell20091362215233<p>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</p>LewisBPBurgeCBBartelDPCell200512011520<p>microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7</p>ChenJFTaoYLiJDengZYanZXiaoXWangDZJ Cell Biol20101905867879<p>Muscle-specific microRNA miR-206 promotes muscle differentiation</p>KimHKLeeYSSivaprasadUMalhotraADuttaAJ Cell Biol20061745677687<p>Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells</p>FrankelLBChristoffersenNRJacobsenALindowMKroghALundAHJ Biol Chem2008283210261033<p>MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells</p>YaoQXuHZhangQQZhouHQuLHBiochem Biophys Res Commun20093883539542<p>MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue</p>KimYJHwangSJBaeYCJungJSStem cells (Dayton, Ohio)2009271230933102<p>MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue</p>RoySKhannaSHussainSRBiswasSAzadARinkCGnyawaliSShiloSNuovoGJSenCKCardiovasc Res20098212129<p>An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation</p>TalottaFCimminoAMatarazzoMRCasalinoLDe VitaGD’EspositoMDi LauroRVerdePOncogene20092817384<p>Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21</p>HatleyMEPatrickDMGarciaMRRichardsonJABassel-DubyRvan RooijEOlsonENCancer Cell2010183282293<p>STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer</p>IliopoulosDJaegerSAHirschHABulykMLStruhlKMol Cell2010394493506<p>miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention</p>SrivastavaNManvatiSSrivastavaAPalRKalaiarasanPChattopadhyaySGochhaitSDuaRBamezaiRNBreast Cancer Res2011132R39<p>miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3′UTR microRNA recognition elements</p>LalANavarroFMaherCAMaliszewskiLEYanNO’DayEChowdhuryDDykxhoornDMTsaiPHofmannOMol Cell2009355610625<p>Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development</p>ToKHPajovicSGallieBLTheriaultBLBMC Cancer20121269<p>Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs</p>DogarAMTowbinHHallJJ Biol Chem2011286181644716458<p>miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors</p>Melkman-ZehaviTOrenRKredo-RussoSShapiraTMandelbaumADRivkinNNirTLennoxKABehlkeMADorYEMBO J2011305835845<p>Downregulation of BCL2 by miRNAs augments drug induced apoptosis: Combined computational and experimental approach</p>SinghRSainiNJ Cell Sci2012<p> <b>Downregulation of BCL2 by miRNAs augments drug induced apoptosis: Combined computational and experimental approach</b> </p>SinghRSainiNJ Cell Sci2012125615681578<p> <b>MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein</b> </p>ZhuYLuYZhangQLiuJJLiTJYangJRZengCZhuangSMNucleic Acids Res2011401046154625<p>The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo</p>HuseJTBrennanCHambardzumyanDWeeBPenaJRouhanifardSHSohn-LeeCle SageCAgamiRTuschlTGenes Dev2009231113271337<p>MicroRNA profiling during mouse ventricular maturation: a role for miR-27 modulating Mef2c expression</p>ChinchillaALozanoEDaimiHEstebanFJCristCAranegaAEFrancoDCardiovasc Res201189198108<p>MicroRNA-27a regulates beta cardiac myosin heavy chain gene expression by targeting thyroid hormone receptor beta1 in neonatal rat ventricular myocytes</p>NishiHOnoKHorieTNagaoKKinoshitaMKuwabaraYWatanabeSTakayaTTamakiYTakanabe-MoriRMol Cell Biol2011314744755<p> <b>MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells</b> </p>LeeJJDrakakiAIliopoulosDStruhlKOncogene2011313338183825<p>Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells</p>GuttillaIKWhiteBAJ Biol Chem2009284352320423216<p>Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells</p>YuFDengHYaoHLiuQSuFSongEOncogene2010292941944204<p>The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells</p>JoglekarMVPatilDJoglekarVMRaoGVReddyDNMitnalaSShoucheYHardikarAAIslets200912137147<p>Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas</p>BraunJHoang-VuCDralleHHuttelmaierSOncogene2010292942374244<p>miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling</p>DuistersRFTijsenAJSchroenBLeendersJJLentinkVVan Der MadeIHeriasVVan LeeuwenRESchellingsMWBarenbrugPCirc Res20091042170178176p following 178<p>MicroRNA-mediated regulation of Ubc9 expression in cancer cells</p>WuFZhuSDingYBeckWTMoYYClin Cancer Res200915515501557<p>Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis</p>ZaragosiLEWdziekonskiBBrigandKLVillageoisPMariBWaldmannRDaniCBarbryPGenome Biol2011127R64<p>miR-30 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1</p>ZhangJZhangHLiuJTuXZangYZhuJChenJDongLZhangJBiochem Biophys Res Commun2012417311001105<p>MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a</p>ZhangYChaoTLiRLiuWChenYYanXGongYYinBLiuWQiangBJournal of molecular medicine (Berlin, Germany)20098714351<p> <b>MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function</b> </p>DonzelliSFontemaggiGFaziFDi AgostinoSPadulaFBiagioniFMutiPStranoSBlandinoGCell Death Differ201119610381048<p>MicroRNA-128 downregulates Bax and induces apoptosis in human embryonic kidney cells</p>AdlakhaYKSainiNCell Mol Life Sci201168814151428<p>Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells</p>GuidiMMuinos-GimenoMKagerbauerBMartiEEstivillXEspinosa-ParrillaYBMC Mol Biol20101195<p>A microRNA signature for a BMP2-induced osteoblast lineage commitment program</p>LiZHassanMQVoliniaSvan WijnenAJSteinJLCroceCMLianJBSteinGSProc Natl Acad Sci USA2008105371390613911<p>The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer</p>YoshinoHChiyomaruTEnokidaHKawakamiKTataranoSNishiyamaKNohataNSekiNNakagawaMBr J Cancer20111045808818<p> <b>The functional significance of miR-1 and miR-133a in renal cell carcinoma</b> </p>KawakamiKEnokidaHChiyomaruTTataranoSYoshinoHKagaraIGotandaTTachiwadaTNishiyamaKNohataNEur J Cancer2011486827836<p>miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer</p>ChiyomaruTEnokidaHTataranoSKawaharaKUchidaYNishiyamaKFujimuraLKikkawaNSekiNNakagawaMBr J Cancer20101025883891<p> <b>Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer</b> </p>ChiyomaruTEnokidaHKawakamiKTataranoSUchidaYKawaharaKNishiyamaKSekiNNakagawaMUrol Oncol2010304434443<p>Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells</p>RaoPKMissiagliaEShieldsLHydeGYuanBShepherdCJShipleyJLodishHFFASEB J201024934273437<p> <b>MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines</b> </p>UchidaYChiyomaruTEnokidaHKawakamiKTataranoSKawaharaKNishiyamaKSekiNNakagawaMUrol Oncol2011311115123<p>MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development</p>BoutzPLChawlaGStoilovPBlackDLGenes Dev20072117184<p>A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2</p>ZhangYXieRLCroceCMSteinJLLianJBvan WijnenAJSteinGSProc Natl Acad Sci USA20111082498639868<p> <b>MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation</b> </p>HuangJZhaoLXingLChenDStem cells (Dayton, Ohio)2010282357364<p>Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1</p>ChungTKLauTSCheungTHYimSFLoKWSiuNSChanLKYuMYKwongJDoranGInt J Cancer2012<p>A microRNA contribution to aberrant Ras activation in gastric cancer</p>LamEKWangXShinVYZhangSMorrisonHSunJNgEKYuJJinHAmerican journal of translational research201132209218<p>MicroRNA-204/211 alters epithelial physiology</p>WangFEZhangCMaminishkisADongLZhiCLiRZhaoJMajerciakVGaurABChenSFASEB J201024515521571<p>Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells</p>LiGLunaCQiuJEpsteinDLGonzalezPInvest Ophthalmol Vis Sci201152629993007<p>Role for miR-204 in human pulmonary arterial hypertension</p>CourboulinAPaulinRGiguereNJSaksoukNPerreaultTMelocheJPaquetERBiardelSProvencherSCoteJJ Exp Med20112083535548<p>Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal</p>LuYRoySNuovoGRamaswamyBMillerTShapiroCJacobSTMajumderSJ Biol Chem2011286494229242302<p>MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma</p>ZhangCZZhangJXZhangALShiZDHanLJiaZFYangWDWangGXJiangTYouYPMol Cancer20109229<p>MicroRNAs modulate the angiogenic properties of HUVECs</p>PolisenoLTuccoliAMarianiLEvangelistaMCittiLWoodsKMercatantiAHammondSRainaldiGBlood2006108930683071<p>MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways</p>RaoXDi LevaGLiMFangFDevlinCHartman-FreyCBurowMEIvanMCroceCMNephewKPOncogene201130910821097<p>miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu</p>QuintavalleCGarofaloMZancaCRomanoGIaboniMDel Basso De CaroMMartinez-MonteroJCIncoronatoMNuovoGCroceCMOncogene2012317858868<p>Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency</p>PolesskayaACuvellierSNaguibnevaIDuquetAMossEGHarel-BellanAGenes Dev200721911251138<p>Expression profiling and identification of novel genes involved in myogenic differentiation</p>TomczakKKMarinescuVDRamoniMFSanoudouDMontanaroFHanMKunkelLMKohaneISBeggsAHFASEB J2004182403405<p>Genome-wide examination of myoblast cell cycle withdrawal during differentiation</p>ShenXCollierJMHlaingMZhangLDelshadEHBristowJBernsteinHSDev Dyn20032261128138<p>Dynamic gene expression during the onset of myoblast differentiation in vitro</p>DelgadoIHuangXJonesSZhangLHatcherRGaoBZhangPGenomics2003822109121<p>Gene discovery by microarray: identification of novel genes induced during growth factor-mediated muscle cell survival and differentiation</p>KuningerDKuzmickasRPengBPintarJERotweinPGenomics2004845876889<p>Gene expression changes during mouse skeletal myoblast differentiation revealed by transcriptional profiling</p>MoranJLLiYHillAAMountsWMMillerCPPhysiol Genomics2002102103111<p>Distinctive morphological and gene/protein expression signatures during myogenesis in novel cell lines from extraocular and hindlimb muscle</p>PorterJDIsraelSGongBMerriamAPFeuermanJKhannaSKaminskiHJPhysiol Genomics2006243264275<p>Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration</p>GoetschSCHawkeTJGallardoTDRichardsonJAGarryDJPhysiol Genomics2003143261271<p>Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines</p>RuikeYIchimuraATsuchiyaSShimizuKKunimotoROkunoYTsujimotoGJ Hum Genet2008536515523<p>Experimental strategies for microRNA target identification</p>ThomsonDWBrackenCPGoodallGJNucleic Acids Res2011391668456853<p>Experimental validation of miRNA targets</p>KuhnDEMartinMMFeldmanDSTerryAVJrNuovoGJEltonTSMethods (San Diego, Calif20084414754<p>Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies</p>ZhuCHMoulyVCooperRNMamchaouiKBigotAShayJWDi SantoJPButler-BrowneGSWrightWEAging Cell200764515523<p>A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy</p>PetrovAVAllinneJPirozhkovaIVLaoudjDLipinskiMVassetzkyYSGenome Res20081813945<p>Mammalian microRNAs: experimental evaluation of novel and previously annotated genes</p>ChiangHRSchoenfeldLWRubyJGAuyeungVCSpiesNBaekDJohnstonWKRussCLuoSBabiarzJEGenes Dev201024109921009<p>Sequence requirements for micro RNA processing and function in human cells</p>ZengYCullenBRRNA (New York, NY200391112123<p>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</p>LivakKJSchmittgenTDMethods2001254402408<p>Processing of gene expression data generated by quantitative real-time RT-PCR</p>MullerPYJanovjakHMiserezARDobbieZBiotechniques2002326137213741376, 1378–1379<p>The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on</p>ChomczynskiPSacchiNNat Protoc200612581585<p>Limma: linear models for microarray data</p>SmythGKBioinformatics and Computational Biology Solutions unsing R and BioconductorNew York: SpringerGentleman R, Carey V, Dudoit S, Huber W2005397420<p>Prediction of mammalian microRNA targets</p>LewisBPShihIHJones-RhoadesMWBartelDPBurgeCBCell20031157787798